JP2023138660A5 - - Google Patents

Download PDF

Info

Publication number
JP2023138660A5
JP2023138660A5 JP2023129040A JP2023129040A JP2023138660A5 JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5 JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5
Authority
JP
Japan
Prior art keywords
cells
recombinant
population
subject
follistatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023129040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023138660A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/022821 external-priority patent/WO2019178613A1/en
Application filed filed Critical
Publication of JP2023138660A publication Critical patent/JP2023138660A/ja
Publication of JP2023138660A5 publication Critical patent/JP2023138660A5/ja
Priority to JP2025203919A priority Critical patent/JP2026026184A/ja
Withdrawn legal-status Critical Current

Links

JP2023129040A 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 Withdrawn JP2023138660A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203919A JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862644362P 2018-03-16 2018-03-16
US201862644356P 2018-03-16 2018-03-16
US62/644,362 2018-03-16
US62/644,356 2018-03-16
PCT/US2019/022821 WO2019178613A1 (en) 2018-03-16 2019-03-18 B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
JP2020548962A JP2021515576A (ja) 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020548962A Division JP2021515576A (ja) 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203919A Division JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Publications (2)

Publication Number Publication Date
JP2023138660A JP2023138660A (ja) 2023-10-02
JP2023138660A5 true JP2023138660A5 (https=) 2025-03-03

Family

ID=65995892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548962A Pending JP2021515576A (ja) 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2023129040A Withdrawn JP2023138660A (ja) 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2025203919A Pending JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020548962A Pending JP2021515576A (ja) 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203919A Pending JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Country Status (7)

Country Link
US (1) US20210047619A1 (https=)
EP (1) EP3765601A1 (https=)
JP (3) JP2021515576A (https=)
CN (1) CN111936617A (https=)
AU (2) AU2019233929B2 (https=)
CA (1) CA3093716A1 (https=)
WO (1) WO2019178613A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
BR112019022473A2 (pt) * 2017-04-27 2020-10-20 Immusoft Corporation células b para liberação in vivo de agentes terapêuticos e dosagens destas
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
EP3914265A4 (en) * 2019-01-23 2023-02-01 The General Hospital Corporation B-CELL IMMUNOTHERAPY
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
WO2025047766A1 (ja) * 2023-08-29 2025-03-06 富士フイルム株式会社 ウイルスの製造方法および細胞への核酸導入方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
DE4223128C2 (de) 1991-07-15 1995-06-14 Handtmann Albert Maschf Verfahren und Vorrichtung zum Vereinzeln und Aufbringen einer Darmraupe auf ein Füllrohr
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2438500C (en) 2001-02-19 2009-09-08 Pola Chemical Industries Inc. Composition for electroporation
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CN1929734A (zh) * 2002-02-21 2007-03-14 惠氏公司 含卵泡抑素区的蛋白质
WO2003080809A2 (en) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20070134796A1 (en) 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
US7799555B2 (en) 2006-02-10 2010-09-21 Bio-Rad Laboratories, Inc. Apparatus for high-throughput electroporation
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
US8551780B2 (en) 2008-02-01 2013-10-08 H. Lee Moffitt Cancer Center & Research Institute, Inc. Electroporation buffer composition and method of use
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
US8133727B2 (en) 2008-11-21 2012-03-13 California Institute Of Technology In vitro human B lymphopoiesis culture system
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9074223B2 (en) 2010-01-08 2015-07-07 Immusoft Corporation Vectors and methods for transducing B cells
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8633029B2 (en) 2010-03-15 2014-01-21 Yamaguchi University Agent for improving gene transfer efficiency to mammalian cells
JP6188728B2 (ja) * 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
ES2715710T3 (es) * 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US10010498B2 (en) * 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EA202090632A1 (ru) * 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
US10842886B2 (en) * 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
DK3234107T3 (da) * 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
WO2016118780A1 (en) * 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CA2992551A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells

Similar Documents

Publication Publication Date Title
JP2023138660A5 (https=)
TWI908706B (zh) ＣＡＲＴｙｒｉｎ組成物和使用方法
JP7490704B2 (ja) 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法
JP2021515576A5 (https=)
JP2021507703A (ja) Ｖｃａｒ組成物とその利用法
EP4284932A1 (en) Gene silencing
US12030922B2 (en) IL-31 improves efficacy of macrophage-based adoptive cell therapy for cancer
JP2021532776A5 (https=)
JP2020517692A5 (https=)
CN115552019A (zh) 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体
US20220127575A1 (en) Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches
CA2549394A1 (en) Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and uses thereof
CN111499766A (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
US20250270546A1 (en) Guide rnas and uses thereof
CN120225548A (zh) 嵌合CD8-α共受体组合物和使用方法
EP3635098B1 (en) T-cells modified to overexpress phf19
JP2023548118A5 (https=)
Ansorge et al. Towards continuous bioprocessing of lentiviral vectors
RU2020133851A (ru) B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц
Baumeister et al. Gene and Cell Therapy: How to Build a BioDrug
WO2026090544A1 (en) Gene silencing
WO2025221789A1 (en) Compositions and methods for use in car/tcr cell therapies
TW202609050A (zh) 用於ｃａｒ／ｔｃｒ細胞療程之組成物及方法
WO2025072717A1 (en) Treating cancer
CN119799717A (zh) 核酸形式il-9联合免疫检查点药物的制剂组合与应用